

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

AMENDMENTS TO THE CLAIMS
(including complete listing of the claims)

1. (Canceled)
2. (Canceled)
3. (Canceled)
4. (Canceled)
5. (Canceled)
6. (Currently Amended) ~~A~~The method as described in ~~of~~ claim 5-11, wherein said mutation in the E1A-CR2 region is in Ad5 and comprises a deletion or substitution of one or more amino acids 122 through 129 encoded by said E1A-CR2 region.
7. (Currently Amended) ~~A~~The method as described in ~~of~~ claim 5-11, wherein said mutation in the E1A-CR2 region ~~is in Ad5 and~~ comprises a deletion or substitution of one or more amino acids 111 through 123.
8. (Currently Amended) ~~A~~The method as described in ~~of~~ claim 5-11, wherein said adenovirus is dl922/947.
9. (Currently Amended) ~~A~~The method as described in ~~of~~ claim 5-11, wherein said adenovirus is dl1107.
10. (Currently Amended) ~~A~~The method as described in ~~of~~ claim 5-11, wherein said adenovirus is pm928.

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

11. (Original) In a cell population comprising dividing and quiescent endothelial cells, a method for killing said dividing endothelial cells with substantially less killing of said quiescent endothelial cells, said method comprising contacting said cell population under infective conditions with a replication competent adenovirus, said adenovirus comprising a mutation in an E1A CR2 RB family member binding region of said adenovirus, and allowing sufficient time for said mutant adenovirus to infect said cell population, wherein said mutant adenovirus replicates to higher titers in said dividing cells than wild type adenovirus.

12. (Currently Amended) A method for substantially and selectively killing dividing endothelial cells and cancer cells compared to quiescent endothelial cells in a cell population comprising said three cell types, said method comprising contacting said cell population under infective conditions with a replication competent adenovirus comprising a mutation in an E1A-CR2 RB family member binding region of said adenovirus, and allowing sufficient time for said mutant adenovirus to infect said cell population.

13. (Currently Amended) ~~A~~ ~~The method as described in~~ of claim 12, wherein said dividing endothelial cells are microvascular endothelial cells.

14. (Canceled)

15. (Currently Amended) A method for controlling angiogenesis in an animal by substantially and selectively killing dividing microvascular endothelial cells compared to quiescent microvascular endothelial cells, said method comprising administering to said animal in need of said control a replication competent adenovirus comprising a mutation in an E1A-CR2 RB family member binding region of said adenovirus, and allowing sufficient time for said mutant adenovirus to infect said microvascular endothelial cells.

16. (Canceled)

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

17. (Currently Amended) ~~A The method as described in~~ claim 16-15, wherein said mutation in the E1A-CR2 region is in Ad5 and comprises a deletion or substitution of one or more amino acids 122 through 129.

18. (Currently Amended) ~~A The method as described in~~ claim 16-15, wherein said mutation in the E1A-CR2 region is in Ad5 and comprises a deletion or substitution of one or more amino acids 111 through 123.

19. (Currently Amended) ~~A The method as described in~~ claim 16-15, wherein said adenovirus is dl922/947.

20. (Currently Amended) ~~A The method as described in~~ claim 16-15, wherein said adenovirus is dl1107.

21. (Canceled)

22. (Previously Presented) A pharmaceutical composition comprising a Rb binding site adenoviral mutant in a physiological solution, wherein said adenoviral mutant is dl922/947.

23. (Previously Presented) A pharmaceutical composition comprising a Rb binding site adenoviral mutant in a physiological solution, wherein said adenoviral mutant is dl1107.

24. (Canceled)

25. (Canceled)

Onyx Dkt No. 1046.ORD
USSN: 09/410,462
PATENT

26. (Previously Presented) A composition comprising a Rb binding site adenoviral mutant with a negative selection agent operably linked to a promoter, wherein said mutant is dl922/947.

27. (Previously Presented) A composition comprising a Rb binding site adenoviral mutant with a negative selection agent operably linked to a promoter, wherein said mutant is dl1107.

28. (Previously Presented) A composition comprising a Rb binding site adenoviral mutant with a negative selection agent operably linked to a promoter, wherein said mutant is pm928.

29. (New) The method of claim 12, wherein said mutation in the E1A-CR2 region is in Ad5 and comprises a deletion or substitution of one or more amino acids 122 through 129 encoded by said E1A-CR2 region.

30. (New) The method of claim 12, wherein said mutation in the E1A-CR2 region is in Ad5 and comprises a deletion or substitution of one or more amino acids 111 through 123.

31. (New) The method of claim 12, wherein said adenovirus is dl922/947.

32. (New) The method of claim 12, wherein said adenovirus is dl1107.

33. (New) The method of claim 12, wherein said adenovirus is pm928.

34. (New) The method of claim 15, wherein said adenovirus is pm928.